Findings on Doxorubicin Therapy Detailed by Investigators at Wuhan University (Folic acid-conjugated iron oxide porous nanorods loaded with doxorubicin for targeted drug delivery)
By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Drugs and Therapies have been presented. According to news reporting out of Hubei, People's Republic of China, by NewsRx editors, research stated, "Iron oxide porous nanorods (IOPNR) with lengths ranging from 40 nm to 60 nm and pore diameters ranging from 5 nm to 10 nm were prepared, and further modified with NH2-PEG-FA (FA-PEG-IOPNR) for ligand targeting and modified with NH2-PEG-OCH3 (PEG-IOPNR) as a control. Instead of chemical bonding, doxorubicin (DOX), a low water solubility anticancer drug, was loaded in the pores of the modified IOPNR because of their porous structure and high porosity."
Our news journalists obtained a quote from the research from Wuhan University, "The release of DOX in acidic PBS solution (pH 5.3) was faster than that in neutral (pH 7.4) solution. The analysis results from TEM, inductively coupled plasma emission spectroscopy, confocal laser scanning microscopy, and flow cytometry analyses indicated that the presence of FA on the surface of the nanorods increase the cellular uptake of nanorods in the case of HeLa cells, a folate receptor (FR)-positive cell line. In contrast, for COS 7 cells, a FR-negative cell line, FA ligand on the surface of the nanorods showed no effect on the cellular uptake. MIT assay indicated that the cytotoxicity of DOX loaded in FA-PEG-IOPNR to HeLa cells was higher than that of DOX in PEG-IOPNR. In the case of COS 7 cells, no significant difference between the cytotoxicity of DOX loaded in FA-PEG-IOPNR and PEG-IOPNR was found."
According to the news editors, the research concluded: "These results suggested that FA-PEG-IOPNR had the potential for target delivery of chemotherapeutic into cancer cells."
For more information on this research see: Folic acid-conjugated iron oxide porous nanorods loaded with doxorubicin for targeted drug delivery. Colloids and Surfaces B-Biointerfaces, 2014;120():142-151. Colloids and Surfaces B-Biointerfaces can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands (see also Drugs and Therapies).
Our news journalists report that additional information may be obtained by contacting P. Yu, Wuhan University, Dept. of Chem, Wuhan 430072, Hubei, People's Republic of China. Additional authors for this research include X.M. Xia, M. Wu, C. Cui, Y. Zhang, L. Liu, B. Wu, C.X. Wang, L.J. Zhang, X. Zhou, R.X. Zhuo and S.W. Huang.
Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Pharmaceuticals, Hubei, Folic Acid, Drugs and Therapies, Doxorubicin Hydrochloride, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC